Cash conversion trending down
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Importance 64 / 95 · cash quality
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Importance 64 / 95 · cash quality
Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.
Importance 64 / 95 · growth
Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).
Importance 54 / 95 · growth
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 12.3% a year over 4 years, from ₹6,742 cr in FY2022 to ₹10,712 cr in FY2026. Net profit grew 22.0% a year over the same period.
Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).
Over 4 years profit compounded at 28.8% a year while revenue compounded at 13.2% a year — though FY2023 saw a one-off step-change of 60% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Revenue grew 21.4% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,979 cr (up 50.8% on the same quarter last year) and net profit ₹534 cr (down 9.6%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹4,979 cr, up 50.8% from ₹3,302 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 EBIT was ₹1,047 cr, up 22.9% from ₹852 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
Q2 FY27 interest (finance cost) was ₹300 cr, up 525.0% from ₹48 cr a year earlier.
Rule QTR_INTEREST_EXPENSE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 2,809 | +2.8% | 503 | +13.5% | 17.9% |
| Q4 FY25 | 2,959 | +7.8% | 498 | +10.9% | 16.8% |
| Q1 FY26 | 3,178 | +11.2% | 548 | +19.9% | 17.2% |
| Q2 FY26 | 3,302 | — | 591 | — | 17.9% |
| Q3 FY26 | 3,303 | +17.6% | 635 | +26.2% | 19.2% |
| Q4 FY26 | 4,197 | +41.8% | 364 | −26.9% | 8.7% |
| Q1 FY27 | 4,921 | +54.8% | 566 | +3.3% | 11.5% |
| Q2 FY27 | 4,979 | +50.8% | 534 | −9.6% | 10.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 38.0% in FY2026, against 34.2% in FY2022. ROE was 27.3% and ROCE 20.2% in FY2026.
ROE declined from 26.5% to 17.0% year on year.
Rule ROE_DETERIORATED_YOY
Debt-to-equity was 1.68x in FY2026, against 0.53x in FY2022; interest coverage 9.70x. Operating cash flow was 1.25x net profit.
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Rule CASH_CONVERSION_DETERIORATING
Net worth compounded at 31.1% a year over 4 years (₹5,953 → ₹17,585) — though FY2026 saw a one-off step-change of 132% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.41×).
Debt-to-equity rose from 0.40× to 0.84× year on year.
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 4 of 12 on return on equity and 5 of 12 on EBITDA margin. Its P/E of 75.8 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
TORNTPHARM · 4th of 12 · set median 14.8%
TORNTPHARM · 5th of 12 · set median 28.7%
TORNTPHARM · 4th of 12 · set median 14.4%
TORNTPHARM · 9th of 12 · set median 45.3×
Trades at 75.77× earnings — 67% above the pharmaceuticals median of 45.29×.
Rule PE_ABOVE_PEERS
On the trailing twelve months. Last full year: P/E 74.4× · P/S 11.4× · ROE 17.0%. TTM and full-year revenue and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 26.3% over 1 year, up 122% over 3 years (30.4% a year) and up 237% over 5 years (27.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.3% below its 52-week high.
Over 4 years profit (28.8% a year) and the stock (30.4% a year) compounded at roughly the same rate — but FY2022 profit (₹777) was well below the through-cycle level (~₹1,656), so this rate is inflated by the recovery from a low base.
Rule STOCK_TRACKED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6,742 | 7,695 | 8,533 | 9,682 | 10,712 |
| Total income | 6,946 | 7,777 | 8,624 | 9,714 | 10,730 |
| EBITDA | 2,304 | 2,547 | 2,981 | 3,607 | 4,072 |
| Profit before tax | 1,466 | 1,577 | 1,917 | 2,610 | 2,897 |
| Net profit | 991 | 1,052 | 1,357 | 1,888 | 2,192 |
| EPS (₹) | 58.6 | 31.1 | 40.1 | 55.8 | 64.8 |
| Net worth | 6,346 | 6,456 | 6,829 | 7,592 | 8,452 |
| Total debt | 3,344 | 4,566 | 3,333 | 2,547 | 14,164 |
| Operating cash flow | 2,140 | 2,266 | 2,893 | 2,574 | 2,731 |
| Free cash flow | 2,035 | 1,850 | 2,581 | 2,146 | 2,262 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 14.1 | 10.9 | 13.5 | 10.6 |
| Profit growth YoY | — | 6.2 | 29.0 | 39.1 | 16.1 |
| Profitability | |||||
| EBITDA margin % | 34.2 | 33.1 | 34.9 | 37.3 | 38.0 |
| Net margin % | 14.3 | 13.5 | 15.7 | 19.4 | 20.4 |
| Return on equity % | 15.6 | 16.4 | 20.4 | 26.2 | 27.3 |
| Return on capital % | 17.6 | 18.1 | 21.0 | 28.0 | 20.2 |
| Leverage & cash | |||||
| Debt to equity | 0.53 | 0.71 | 0.49 | 0.34 | 1.68 |
| Cash flow ÷ profit | 2.16 | 2.15 | 2.13 | 1.36 | 1.25 |
| Current ratio | 1.62 | 1.15 | 1.25 | 1.46 | 1.07 |